NCT02970032View on ClinicalTrials.gov

Evaluation of Anti-Xa Levels in Surgery Patients Receiving Fixed Dose Heparin

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 10, 2016

Primary Completion Date

September 10, 2017

Study Completion Date

December 8, 2017

Conditions
Deep-Venous ThrombosisPulmonary EmbolismVenous Thromboembolism
Interventions
DRUG

Real time heparin dose adjustment

Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.

DRUG

Standard heparin dose

Patients will be placed on heparin infusions per their surgeon's discretion.

Trial Locations (1)

84132

Univeristy of Utah Hospital, Salt Lake City

All Listed Sponsors
lead

University of Utah

OTHER

NCT02970032 - Evaluation of Anti-Xa Levels in Surgery Patients Receiving Fixed Dose Heparin | Biotech Hunter | Biotech Hunter